Clinical Trial

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of ABSK112 in patients with NSCLC to evaluate the safety, tolerability, PK, and preliminary antitumor efficacy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-17.
Trial Details
NCT Number NCT06225804
Lead Sponsor Abbisko Therapeutics Co, Ltd
Conditions Non-Small Cell Lung Cancer
Enrollment 164 participants
Start Date 2024-02-22
Primary Completion 2027-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2024-03-18